Orlando, FL -- (SBWIRE) -- 09/12/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Oclaro, Inc. (NASDAQ:OCLR), Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG).
Oclaro, Inc. (NASDAQ:OCLR) shares climbed 39.62% to $1.48. The company announced that on September 16, 2013 at 5:00 p.m.Eastern Timethe Company will host a conference call to discuss the recently announced asset sale and its financial results for the fourth quarter and fiscal year 2013, which ended June 29, 2013.
Additionally, Laser and optics manufacturer II-VI Inc. on Sept. 12 has acquired the semiconductor laser business of Oclaro Inc. for $92 million. II-VI is acquiring semiconductor laser technology used in laser system products for material processing, medical, consumer and fiber optic communications. The Swiss company will be operated as II-VI Laser Enterprise GmbH.
As part of the deal, Oclaro retained $15 million in accounts receivable. In addition, $6 million of cash is being held back by II-VI for 15 months and another $2 million is being held back by II-VI for potential working capital adjustments.
Are investors worried about the recent updates with OCLR? Find out with a free trend analysis HERE
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) stock jumped 10.53% to $3.57. The company on Sept. 10 reports financial results for the six months ended June 30, 2013. For the six months ended June 30, 2013, the Company recorded revenues from continuing operations of $193,000, a nearly four-fold increase compared with $51,000 for the first six months of 2012. The operating loss for the first six months of 2013 was $6.7 million, including $467,000 of non-cash stock-compensation expense. This compares with an operating loss for the first six months of 2012 of $3.4 million, including $158,000 of non-cash stock-compensation expense.
Additionally, the company on Sept. 9 announces that the Company has executed credentialing agreements with FedMed, Inc. (FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta's Cancer Origin Test™. FedMed is a Preferred Provider Organization (PPO) with over 550,000 physicians, 4,000 hospitals and 60,000 Ancillary Care Providers nationwide.
Is ROSG going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)